Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114897 | 0.84 | CYP3A4 (0.50) | KMOTSHRCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1115058 | 0.83 | GAA (0.46) | GAAKMOTSHRCYP3A4CYP2C19 | |
| SCHEMBL1115118 | 0.79 | TSHR (0.51) | TSHRCYP3A4CYP2C19CYP2C9SCD | |
| SCHEMBL1115109 | 0.77 | SCD (0.77) | GAAKMOCYP3A4CYP2C19CYP2C9 | |
| SCHEMBL5799186 | 0.77 | KMO (0.52) | GAAKMOTSHRCYP3A4CYP2C19 | |
| SCHEMBL8263744 | 0.76 | HTT (0.71) | KMOTSHRCYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL13657563 | 0.76 | TSHR (0.39) | GAAKMOTSHRCYP3A4CYP2C19 | |
| SCHEMBL1114922 | 0.76 | SCD (0.49) | GAAKMOTSHRCYP3A4CYP2C19 | |
| SCHEMBL13651640 | 0.76 | SCD (0.49) | GAAKMOTSHRCYP3A4CYP2C19 | |
| SCHEMBL8265365 | 0.76 | POLB (0.56) | GAAKMOTSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278976-A1 | 2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126527-A1 | 2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126527-A1 | 2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253693-A1 | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253693-A1 | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253693-A1 | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253693-A1 | 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | GAA 560/4885KMO 431/4885TSHR 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.